Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1802 in advanced malignancy
NCT04414150Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-1802 in solid tumor (advanced stage), sponsored by Hengrui. Primary endpoint: Dose limiting toxicity. Started Jun 2020; status: completed.
02
Drugs
SHR-1802
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04414150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04414150.